(E)-(4-methylphenethyl) 3-(3,4-dihydroxyphenyl)acrylate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-(4-methylphenethyl) 3-(3,4-dihydroxyphenyl)acrylate
• 英文别名: 2-(4-methylphenyl)ethyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
• 化学式: C₁₈H₁₈O₄
• 分子量: 298.339
• InChiKey: VHELPFGUSXOBJK-VQHVLOKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对甲基苯乙酸 在 lithium aluminium tetrahydride 、 ytterbium(III) triflate 作用下， 以 四氢呋喃 、 硝基甲烷 为溶剂， 反应 4.5h， 生成 (E)-(4-methylphenethyl) 3-(3,4-dihydroxyphenyl)acrylate
  参考文献：
  名称：

  具有单取代苯基乙醇部分的咖啡酸酯的抗增殖活性和SAR

  摘要：

  合成了一系列具有单取代苯基乙醇部分的CAPE衍生物，并通过MTT分析对4种人类癌细胞系（Hela，DU-145，MCF-7和ECA-109）的生长进行了评估。首次系统地研究了取代基对抗增殖活性的影响。发现苯乙醇部分的2'-位的给电子和疏水取代基可以显着增强CAPE的抗增殖活性。作为一种新型咖啡酸酯的2'-丙氧基衍生物表现出出色的效力（ 分别针对Hela和DU-145的IC 50 = 0.4±0.02和0.6±0.03μM）。

  DOI：

  10.1016/j.bmcl.2016.12.007

文献信息

• A Rapid and Practical Catalytic Esterification for the Preparation of Caffeic Acid Esters
  作者：Dongsheng Xie、Fengzhi Yang、Jin Xie、Man Zhang、Wenlu Liu、Lei Fu

  DOI：10.3184/174751914x14146000527920

  日期：2014.11

  A convenient and practical catalytic method for the preparation of caffeic acid esters is reported. This esterification was carried out with high efficiency in the presence of ytterbium triflate in nitromethane without any other auxiliary reagents. The wide scope of application and especially the higher reactivity and more convenient procedure than previous methods make it a valuable application for the synthesis of caffeic acid esters and other cinnamic acid esters.

  报告中介绍了一种方便实用的催化方法来制备咖啡酸酯。这种酯化反应是在硝基甲烷中三酸镱的存在下高效进行的，无需任何其他辅助试剂。与以前的方法相比，该方法应用范围广，特别是反应活性更高，操作过程更简便，因此在合成咖啡酸酯和其他肉桂酸酯方面具有重要的应用价值。
• Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds
  申请人：Cai R. Zhenhong

  公开号：US20080076738A1

  公开（公告）日：2008-03-27

  Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  本发明公开了至少具有一个膦酸酯基团的新型HIV整合酶抑制剂化合物、其受保护的中间体以及用于抑制HIV整合酶的方法。
• Para-Coumaric Acid or Para-Hydroxycinnamic Acid Derivatives and Their Use in Cosmetic or Dermatological Compositions
  申请人：Okombi Sabrina

  公开号：US20110237551A1

  公开（公告）日：2011-09-29

  The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an —NH— group; X and Y are identical and each represent a CH or CH 2 group, as an active principle with depigmenting, free-radical-scavenging and/or antiinflammatory is activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and/or antiinflammatory activity.

  本发明涉及对香豆酸或对羟基肉桂酸衍生物在化妆品或皮肤科组合物中的使用，具体地，涉及使用至少一种从对香豆酸衍生的化合物，其具有下列通式（I）：其中，特别地，Z表示氧或—NH—基团；X和Y相同，分别表示CH或CH2基团，作为具有脱色、自由基清除和/或抗炎活性的活性原理的用途。本发明还涉及上述化合物在化妆品护理或制备药物组合物中的使用，特别用于脱色皮肤区域，具有抗自由基和/或抗炎活性。
• MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY
  申请人：Universite de Moncton

  公开号：US20190119194A1

  公开（公告）日：2019-04-25

  The present invention relates to modulators of lipoxygenase and/or cyclooxygenase enzyme. The present invention also provides compositions comprising such modulators, and methods therewith for treating lipoxygenase receptor mediated diseases.
• COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH
  申请人：UNIVERSITY OF NEW BRUNSWICK

  公开号：US20220211653A1

  公开（公告）日：2022-07-07

  Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.